Arrowhead Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Pharma Giants' Gross Profit Trends: A Decade in Review

__timestampArrowhead Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014175000116287000
Thursday, January 1, 2015382000136004000
Friday, January 1, 2016158333203017000
Sunday, January 1, 201731407709287023000
Monday, January 1, 201816142321393541000
Tuesday, January 1, 2019168795577376095000
Wednesday, January 1, 202087992066467938000
Friday, January 1, 2021138287000504714000
Saturday, January 1, 2022232810000580017000
Sunday, January 1, 2023240735000523742000
Monday, January 1, 20243551000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Gross Profit Trends

In the competitive landscape of pharmaceuticals, Arrowhead Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have shown intriguing financial trajectories over the past decade. From 2014 to 2023, Supernus Pharmaceuticals consistently outperformed Arrowhead in gross profit, peaking in 2022 with a staggering 580% increase from its 2014 figures. Meanwhile, Arrowhead's journey was more volatile, with a notable surge in 2023, marking a 137% rise from its 2014 baseline.

Key Insights

  • Supernus Pharmaceuticals: Demonstrated robust growth, with gross profits increasing steadily each year, reflecting strong market positioning and product demand.
  • Arrowhead Pharmaceuticals: Experienced fluctuations, yet showed resilience with significant gains in recent years, indicating potential strategic shifts or successful product launches.

This analysis highlights the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can lead to varied financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025